Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Health Insurance News Astrazeneca S Enhertu Breast Cancer Drug Added To China S State Insurance List is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca‘s total revenues) rose 18% in the second quarter of 2025, generating $6.3 ... Read More
AstraZeneca’s HER2-low Breast Cancer Study: Key Insights and Market Implications
AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has recently completed a significant study titled ... Read More
FDA Nod Makes Boehringer Ingelheim Drug an Alternative to AstraZeneca ADC in Lung Cancer
Lung cancer driven by mutated HER2 proteins already has a targeted therapy, the blockbuster product Enhertu from AstraZeneca and Daiichi Sankyo. A Boehringer Ingelheim drug has won FDA approval for ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus